Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap153.76M
Enterprise Value116.39M
Trailing P/E17.94
SPRO
(NASDAQ)Spero Therapeutics, Inc.
$2.63-- (--)
Loading... - Market loading
Spero Therapeutics (SPRO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)2.55
Forward Price/Sales1.81
Price/Book (mrq)2.61
Price/Tangible Book (mrq)2.61
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue1.93
EV/Earnings13.58
EV/EBITDA16.67
EV/EBIT16.67
EV/FCF-9.22
Stock Price
Current price, 52-week range, and moving averages
Current Price$2.63
1-Day Change1.54%
52-Week High$3.22
52-Week Low$0.61
52-Week Change318.03%
YTD Change11.91%
1-Year Change283.49%
50-Day MA$2.54
200-Day MA$2.32
Avg Volume (30 day)533.40K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding59.37M
Book Value per Share$0.99
Net Cash per Share$0.63
FCF per Share$-0.21
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin100.00%
EBITDA Margin (ttm)11.57%
EBIT Margin (ttm)11.57%
Operating Margin (ttm)11.57%
Pretax Margin (ttm)14.63%
Profit Margin (ttm)14.20%
FCF Margin (ttm)-20.91%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)14.52%
Return on Assets (ttm)12.44%
Return on Invested Capital (ttm)31.30%
Return on Capital Employed (ttm)11.63%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue60.38M
Gross Profit60.38M
Operating Income6.98M
Pretax Income8.83M
Net Income8.57M
EBITDA6.98M
EBIT6.98M
Diluted EPS$0.15
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow-12.62M
Free Cash Flow-12.62M
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth34.26%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)68.92M
Cash & Securities (mrq)40.27M
Net Cash (mrq)37.37M
Net Cash per Share$0.63
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)2.90M
Working Capital (mrq)58.42M
Total Equity (mrq)59.02M
Book Value per Share$0.99
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)7.59
Quick Ratio (mrq)7.59
Debt/Equity (mrq)0.05
Debt/EBITDA (ttm)0.41
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield5.57%
FCF Yield-8.21%
Buyback Yield0.00%
Total Shareholder Yield0.00%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score2.39
Piotroski F-Score6/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$1.84
Graham Upside/Downside-30.12%
Frequently Asked Questions About Spero Therapeutics Statistics
What are the key financial metrics for SPRO?
Spero Therapeutics, Inc. (SPRO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is SPRO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Spero Therapeutics is overvalued or undervalued.
How do I read SPRO's profitability ratios?
Spero Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do SPRO's debt ratios indicate?
The financial health section shows Spero Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is SPRO's dividend analysis?
The dividend section covers Spero Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.